PMC Hereditary Prostate Cancer Panel examines genes linked to an increased risk of developing prostate cancer in adulthood. Due to the genetic diversity associated with these conditions| relying solely on physical characteristics can be challenging in pinpointing the exact cause. By conducting a comprehensive panel test| healthcare providers can efficiently assess multiple potential genes considering the overlapping nature of prostate cancer susceptibility conditions. Some genes included in this panel may also be associated with conditions unrelated to the clinical indication for testing.
Targeted Exome/ Slice Exome (Next Generation Sequencing including Copy Number Variation)
120x
All sequencing technologies have limitations. A negative result from this analysis does not rule out a possible genetic diagnosis as some variants may not be detected by this test. This test is not designed to detect low level mosaicism, structural rearrangements, indels >40bp, deep intronic variants of unknown clinical significance, or large cytogenetic CNVs. Certain inherent qualities of the human genome, for example repetitive regions/homopolymers, GC rich, pseudogenes, and rare polymorphisms, pose significant technical challenges such as sequence misalignment that may potentially impact the accuracy of the results. False negative results may also occur in the setting of allogeneic bone marrow, stem cell transplantation, active or chronic hematologic conditions, recent blood transfusions, suboptimal DNA quality or PCR trace contamination. Other potential sources of error include sample mix-ups and clerical issues.